ReviewBriefings in functional genomics & proteomics2008
The plasma proteome, adductome and idiosyncratic toxicity in toxicoproteomics research.
Review in Briefings in functional genomics & proteomics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 37 citations in OpenAlex.
- Blood-borne biomarkers and bioindicators for linking exposure to health effects in environmental health science.Journal of toxicology and environmental health. Part B, Critical reviews · 2016Review
- Glycocapture-assisted global quantitative proteomics (gagQP) reveals multiorgan responses in serum toxicoproteome.Journal of proteome research · 2013Article
- Adductomics: characterizing exposures to reactive electrophiles.Toxicology letters · 2012Article
- The evolution of bioinformatics in toxicology: advancing toxicogenomics.Toxicological sciences : an official journal of the Society of Toxicology · 2011Review
- Profiling Cys34 adducts of human serum albumin by fixed-step selected reaction monitoring.Molecular & cellular proteomics : MCP · 2011Article
- Toxicogenomic profiling of chemically exposed humans in risk assessment.Mutation research · 2010Review
- Genomic indicators in the blood predict drug-induced liver injury.The pharmacogenomics journal · 2010Article
- Overview of extracellular microvesicles in drug metabolism.Expert opinion on drug metabolism & toxicology · 2010Review
- Amplify, amplify: shotgun proteomics boosts the signal for biomarker discovery.Environmental health perspectives · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Toxicoproteomics uses the discovery potential of proteomics in toxicology research by applying global protein measurement technologies to biofluids and tissues after host exposure to injurious agents. Toxicoproteomic studies thus far have focused on protein profiling of major organs and biofluids such as liver and blood in preclinical species exposed to model toxicants. The slow pace of discovery for new biomarkers, toxicity signatures and mechanistic insights is partially due to the limited proteome coverage derived from analysis of native organs, tissues and body fluids by traditional proteomic platforms. Improved toxicoproteomic analysis would result by combining higher data density LC-MS/MS platforms with stable isotope labelled peptides and parallel use of complementary platforms. Study designs that remove abundant proteins from biofluids, enrich subcellular structures and include cell specific isolation from heterogeneous tissues would greatly increase differential expression capabilities. By leveraging resources from immunology, cell biology and nutrition research communities, toxicoproteomics could make particular contributions in three inter-related areas to advance mechanistic insights and biomarker development: the plasma proteome and circulating microparticles, the adductome and idiosyncratic toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.